J Pepe1, C Cipriani2, F P Cantatore3, A Fabbri4, E Pola5, V Vinicola6, O Raimo2, F Biamonte2, R Pascone7, C Ferrara8, S Minisola2. 1. Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. jessica.pepe@uniroma1.it. 2. Department of Internal Medicine and Medical Disciplines, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. 3. Rheumatology Unit, University of Foggia, Foggia, Italy. 4. CTO Andrea Alesini Hospital, ASL Roma 2, University of Rome 'Tor Vergata', Rome, Italy. 5. Policlinico Gemelli Hospital, Rome, Italy. 6. Rehabilitation Hospital, I.R.C.C.S Santa Lucia Foundation, Rome, Italy. 7. Department of Pediatrics, "Sapienza" University, Rome, Italy. 8. Department of Public Health and Infectious Diseases, Section Health Statistic, "Sapienza" University Rome, Rome, Italy.
Abstract
PURPOSE: To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis. METHODS: Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study. RESULTS: At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94). CONCLUSIONS: PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
PURPOSE: To investigate the effect of 18 months' parathyroid hormone 1-84 (PTH 1-84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis. METHODS: Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1-84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study. RESULTS: At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporoticpatients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1-84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1-84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94). CONCLUSIONS:PTH (1-84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
Entities:
Keywords:
Bone morphogenetic protein 4; Osteoporosis; Parathyroid hormone 1–84; Vessel endothelial growth factor
Authors: Natalie E Cusano; Mishaela R Rubin; Chiyuan Zhang; Laura Anderson; Elizabeth Levy; Aline G Costa; Dinaz Irani; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2014-08-19 Impact factor: 5.958
Authors: S Piemonte; E Romagnoli; C Bratengeier; W Woloszczuk; A Tancredi; J Pepe; C Cipriani; S Minisola Journal: J Endocrinol Invest Date: 2012-07-24 Impact factor: 4.256
Authors: Thomas Pufe; Katharina E Scholz-Ahrens; Andreas T M Franke; Wolf Petersen; Rolf Mentlein; Deike Varoga; Bernhard Tillmann; Jürgen Schrezenmeir; Claus C Glüer Journal: Bone Date: 2003-12 Impact factor: 4.398
Authors: Stefan Brunner; Hans Diogenes Theiss; Alfons Murr; Thomas Negele; Wolfgang-Michael Franz Journal: Am J Physiol Endocrinol Metab Date: 2007-10-02 Impact factor: 4.310
Authors: G Christodoulakos; I Lambrinoudaki; C Panoulis; C Papadias; A Sarandakou; T Liakakos; A Alexandrou; G Creatsas Journal: Eur J Endocrinol Date: 2004-08 Impact factor: 6.664
Authors: C Cipriani; J Pepe; F Bertoldo; G Bianchi; F P Cantatore; A Corrado; M Di Stefano; B Frediani; D Gatti; A Giustina; T Porcelli; G Isaia; M Rossini; L Nieddu; S Minisola; G Girasole; M Pedrazzoni Journal: J Endocrinol Invest Date: 2017-09-27 Impact factor: 4.256
Authors: Athanasios D Anastasilakis; Stergios A Polyzos; Polyzois Makras; Martina Rauner; Linda Sonnleitner; Gerhard Hawa; Elena Tsourdi; Maria P Yavropoulou; Albert Missbichler; Evangelos Terpos Journal: J Musculoskelet Neuronal Interact Date: 2019-09-01 Impact factor: 2.041